ICPTUnknown
INTERCEPT PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for INTERCEPT PHARMACEUTICALS, INC. (ICPT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ICPT insiders buying or selling?
INTERCEPT PHARMACEUTICALS, INC. insiders reported no open-market purchases or sales in the last 12 months. Since April 2018, Trabud has recorded 63 Form 4 filings for ICPT: 9 buys ($61.0M) and 54 sells ($542.2M).
Source: SEC EDGAR Form 4
Key Statistics (April 2018 – Mar 13, 2021)
Total Form 4 filings
63
SEC EDGAR
Insider filers
16
Insider buys (9)
$61.0M
Insider sells (54)
$542.2M
Insider sentiment
Net sellingNet insider flow of $481.2M in net selling since April 2018.
Recent ICPT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 13, 2021 | Srinivas Akkaraju | Director | Purchase | 237.0K | $21.17 | $5.0M | SEC ↗ |
| Jan 6, 2021 | Sandip Kapadia | CFO and Treasurer | Sale | 2.2K | $24.47 | $53.7K | SEC ↗ |
| Dec 17, 2020 | Sandip Kapadia | CFO and Treasurer | Sale | 1.8K | $32.78 | $57.8K | SEC ↗ |
| Aug 20, 2020 | Jason Campagna | Chief Medical Officer | Sale | 1.2K | $47.44 | $56.5K | SEC ↗ |
| Aug 18, 2020 | Genextra S.p.A. | 10% Owner | Sale | 1.5M | $47.50 | $71.2M | SEC ↗ |
| Aug 18, 2020 | Francesco Micheli | 10% Owner | Sale | 1.5M | $47.50 | $71.2M | SEC ↗ |
| Aug 18, 2020 | Paolo Fundaro | Director, 10% Owner | Sale | 1.5M | $47.50 | $71.2M | SEC ↗ |
| May 15, 2020 | Paolo Fundaro | Director, 10% Owner | Sale | 595.6K | $84.60 | $50.4M | SEC ↗ |
| May 15, 2020 | Francesco Micheli | 10% Owner | Sale | 595.6K | $84.60 | $50.4M | SEC ↗ |
| May 15, 2020 | Genextra S.p.A. | 10% Owner | Sale | 595.6K | $84.60 | $50.4M | SEC ↗ |
| Apr 29, 2020 | Christian Weyer | EVP, Research & Development | Sale | 181 | $85.95 | $15.6K | SEC ↗ |
| Apr 10, 2020 | David A Ford | Chief Human Resources Officer | Sale | 58 | $70.00 | $4.1K | SEC ↗ |
| Feb 29, 2020 | Christian Weyer | EVP, Research & Development | Sale | 113 | $87.62 | $9.9K | SEC ↗ |
| Jan 28, 2020 | Christian Weyer | EVP, Research & Development | Sale | 723 | $94.04 | $68.0K | SEC ↗ |
| Jan 9, 2020 | Jason Campagna | Chief Medical Officer | Sale | 732 | $113.02 | $82.7K | SEC ↗ |
| Jan 4, 2020 | Mark Pruzanski | President & CEO | Sale | 100 | $125.00 | $12.5K | SEC ↗ |
| Jan 4, 2020 | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Sale | 262 | $125.00 | $32.8K | SEC ↗ |
| Jan 4, 2020 | David A Ford | Chief Human Resources Officer | Sale | 259 | $117.16 | $30.3K | SEC ↗ |
| Dec 31, 2019 | Christian Weyer | EVP, Research & Development | Sale | 1.6K | $123.24 | $194.8K | SEC ↗ |
| Dec 31, 2019 | Mark Pruzanski | President & CEO | Sale | 417 | $125.00 | $52.1K | SEC ↗ |
| Dec 31, 2019 | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Sale | 54 | $125.00 | $6.8K | SEC ↗ |
| Dec 21, 2019 | Jason Campagna | Chief Medical Officer | Sale | 154 | $119.45 | $18.4K | SEC ↗ |
| Dec 3, 2019 | Christian Weyer | EVP, Research & Development | Sale | 1.0K | $101.65 | $105.7K | SEC ↗ |
| Nov 28, 2019 | Christian Weyer | EVP, Research & Development | Sale | 6.2K | $100.00 | $622.8K | SEC ↗ |
| Nov 28, 2019 | Mark Pruzanski | President & CEO | Sale | 50.0K | $100.00 | $5.0M | SEC ↗ |
Showing the 25 most recent of 63 Form 4 filings for INTERCEPT PHARMACEUTICALS, INC..
Most active ICPT insiders
- David Shapiro12 filings
- Christian Weyer10 filings
- Lisa Bright5 filings
- Mark Pruzanski5 filings
- David A Ford4 filings
Ask anything about ICPT insider activity
Use Trabud's AI agent to query INTERCEPT PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me ICPT CEO purchases this year" or compare it against any other ticker.
Open the AI agentICPT insider trading FAQ
Are INTERCEPT PHARMACEUTICALS, INC. insiders buying or selling?
INTERCEPT PHARMACEUTICALS, INC. insiders reported no open-market purchases or sales in the last 12 months. Since April 2018, Trabud has recorded 63 Form 4 filings for ICPT: 9 buys ($61.0M) and 54 sells ($542.2M). Over the full record that is net selling of $481.2M.
How many insiders trade ICPT stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for INTERCEPT PHARMACEUTICALS, INC.. The most recent filing was accepted on Mar 13, 2021.
Where does Trabud get ICPT insider trading data?
All ICPT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.